GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » 12-1 Month Momentum %

Everest Medicines (HKSE:01952) 12-1 Month Momentum % : 111.06% (As of May. 29, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-29), Everest Medicines's 12-1 Month Momentum % is 111.06%.

The industry rank for Everest Medicines's 12-1 Month Momentum % or its related term are showing as below:

HKSE:01952's 12-1 Month Momentum % is ranked better than
94.03% of 1475 companies
in the Biotechnology industry
Industry Median: -25 vs HKSE:01952: 111.06

Competitive Comparison of Everest Medicines's 12-1 Month Momentum %

For the Biotechnology subindustry, Everest Medicines's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Everest Medicines's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Everest Medicines's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Everest Medicines's 12-1 Month Momentum % falls into.



Everest Medicines  (HKSE:01952) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Everest Medicines  (HKSE:01952) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Everest Medicines 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Everest Medicines's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Everest Medicines (HKSE:01952) Business Description

Traded in Other Exchanges
Address
1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.
Executives
Fu Wei 2307 Founder of a discretionary trust who can infl
Nova Aqua Limited 2201 Interest of corporation controlled by you
C-bridge Joint Value Creation Limited 2201 Interest of corporation controlled by you
Everest Management Holding Co., Ltd. 2101 Beneficial owner
Ra Capital Management, L.p. 2102 Investment manager
Kolchinsky Peter 2305 Beneficiary of a trust
Kolchinsky Anna Inge Leonore Haas 2202 Interest of your spouse
Ra Capital Healthcare Fund, L.p. 2101 Beneficial owner
Ra Capital Healthcare Fund Gp, Llc 2201 Interest of corporation controlled by you
Fu Wei 2307 Founder of a discretionary trust who can infl
Janchor Partners Limited 2102 Investment manager
C-bridge Capital Gp, Ltd. 2501 Other
Vistra Trust (singapore) Pte. Limited 2501 Other
C-bridge Capital Gp Iv, Ltd. 2201 Interest of corporation controlled by you
C-bridge Iv Investment Nine Limited 2101 Beneficial owner

Everest Medicines (HKSE:01952) Headlines

No Headlines